Table 3.
Protective immune responses to trivalent vaccination with BoNT Hc vaccines
| Group (n = 5) | Dose | Number of vaccinations | Total amount of DNA administered | C. botulinum neurotoxin serotype used for challengea | Survival against challenge with 102 LD50C. botulinum neurotoxin (%)b |
|---|---|---|---|---|---|
| Naïve | N/A | N/A | N/A | BoNT/A | 0 |
| BoNT/Hc/A + BoNT/Hc/B + BoNT/Hc/E | 10 μg (each) | 2 | 60 μg | BoNT/A | 100 |
| Naïve | N/A | N/A | N/A | BoNT/B | 0 |
| BoNT/Hc/A + BoNT/Hc/B + BoNT/Hc/E | 10 μg (each) | 2 | 60 μg | BoNT/B | 100 |
| Naïve | N/A | N/A | N/A | BoNT/E | 0 |
| BoNT/Hc/A + BoNT/Hc/B + BoNT/Hc/E | 10 μg (each) | 2 | 60 μg | BoNT/E | 100 |
aAnimals were challenged 4 weeks post-final immunization with 200 μl of the respective toxin delivered by intraperitoneal injection.
bAnimals were monitored for survival up to 7 d post-challenge.